Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Alopecia 1

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 20pomalidomide 18Lenalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Cisplatin 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8obinutuzumab 7cemiplimab 7Drug Therapy 7Carboplatin 7zanubrutinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Immunoconjugates × 1 year × Clear all
NCT07051850 2025-07-15

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Seoul St. Mary's Hospital

Recruiting
174 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡